Dimopoulos M, Wang M, Maisnar V, et al. Response, progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018, 11(1):49. doi: 10.1186/s13045-018-0583-7.
Advertisement
Articles by Dimopoulos M, Wang M, Maisnar V, et al. Response, progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018, 11(1):49. doi: 10.1186/s13045-018-0583-7.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
Upcoming 2026-2027 Vaccine Season: Deals, Data, and an FDA Vote
3
House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden
4
Pediatric Cancer Carries Greater Financial Toxicity Than Adult Disease, Driving Calls for Systemic Change
5